The American Cancer Society issued a substantive change to its prostate cancer screening guidance, calling for PSA testing every two years for men aged 50 to 69. The guideline authors reported a particular emphasis on surveillance for Black men and men with a strong family history of prostate cancer, groups the panel identified as carrying elevated risk and disproportionately represented among deaths from the disease. Short, actionable intervals—every two years—are now recommended by the society for this age band.
The study team observed that the guidance reflects a renewed clinical confidence in PSA testing after a period during which clinicians questioned the biomarker’s specificity. The source noted that PSA had fallen out of favor previously but that more recent findings prompted the panel to re-embrace the test. The article did not provide exact PSA thresholds, age-specific stop points, or downstream management protocols tied to screening results; those operational details were not reported in the source.
Senate maneuvering intersected with health policy this week when Sen. Rand Paul announced he will relinquish leadership of the homeland security committee to assume the top Republican slot on the Senate Health, Education, Labor and Pensions Committee next year. The STAT report documented that this move will place Paul in direct policy contention with Sen. Bernie Sanders, who plans to push his party toward supporting Medicare for All when he becomes committee chair. The coverage traced Paul’s prior use of subpoena power on homeland security matters—specifically his role in actions against a former federal official—without alleging new evidence; the source provided this as political context rather than clinical guidance.
Researchers applied a recently proposed framework—one that shifts emphasis from simple height-and-weight ratios to measures of fat distribution, particularly abdominal adiposity—to national obesity estimates in the United States, the United Kingdom, China, and Spain. The investigators analyzed data from 844,000 participants and calculated that a switch away from BMI would reclassify a substantial number of people: BMI-based diagnosis missed 6.2% of adults who would be identified as obese by the alternative metric.
The authors of the study argued that capturing where fat is stored may better reflect mortality risk than BMI alone. The source explained that replacing BMI would increase measured obesity prevalence and could flip diagnoses for millions of people, but it did not list the new metric’s diagnostic cutoffs, nor did it report how clinical workflows should change in practice. The study’s numerical results and the measured 6.2% difference were reported directly in the article.
Two opinion pieces published alongside the news roundup examined MAHA’s tactics and historical influences. One author argued that MAHA has borrowed strategies from Black environmental and health justice activists while simultaneously undermining Black communities, and another argued that the movement’s tolerance of violent figures reflects deeper cultural problems. The STAT item summarized these viewpoints as commentary; it did not present new empirical data or clinical recommendations related to the movement’s positions.
Scientists mining the NIH’s All of Us cohort used genetic data from nearly 100,000 Americans to identify thousands of previously unreported variants in pharmacogenes. The study team observed that every participant carried at least one variant across the 16 pharmacogenes analyzed. Data indicated that about one in four participants had a history of taking medications that could be affected by pharmacogene variation—ranging from selective serotonin reuptake inhibitors to chemotherapy agents.
Investigators attributed the discovery power, in part, to the cohort’s increased genetic diversity. The article did not provide gene-by-gene variant frequencies, specific clinical-actionable allele lists, or implementation guidance for genotype-guided prescribing; those methodological and operational details were not included in the source material.
The newsletter summarized additional reporting and commentary that may be of interest to clinicians and researchers. Items included deeper STAT coverage of the American Cancer Society’s guideline update, a STAT analysis of the obesity metric study, a Science feature questioning global microbial-tracking data, and other pieces on hormone therapy outcomes and political reporting. These listings were presented as editorial recommendations and did not supply new primary data.
Limitations and unanswered questions reported in the source
The STAT article provided summary-level reporting and did not include granular screening parameters for the new PSA guidance—no screening thresholds, no age-based cessation recommendations beyond the 50–69 age band, and no trial data or modeling details in the piece. The obesity-metric study reported a 6.2% discrepancy but the source did not describe the new metric’s cutoffs or operational diagnostic criteria. For the All of Us pharmacogene findings, the article reported participant counts, the number of genes studied (16), and the proportion of participants exposed to affected drugs, but it did not list gene-specific recommendations or implementation steps for pharmacogenomic prescribing.